These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34918264)

  • 21. Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine.
    André FE
    J Infect Dis; 1995 Mar; 171 Suppl 1():S33-9. PubMed ID: 7876646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current status and future trends in vaccine regulation--USA.
    Falk LA; Ball LK
    Vaccine; 2001 Feb; 19(13-14):1567-72. PubMed ID: 11166876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Licensing Requirements for Poultry Veterinary Biologics in the United States.
    Schrader JS; Smith HE
    Avian Dis; 2024 Jan; 67(4):467-473. PubMed ID: 38300665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of Replication-Competent VSV- and Ervebo-Vectored Vaccines Against SARS-CoV-2.
    Liu Q; Ding Z; Lan J; Wong G
    Methods Mol Biol; 2022; 2410():193-208. PubMed ID: 34914048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving vaccine performance with adjuvants.
    Vogel FR
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S266-70. PubMed ID: 10875797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reasons for instability of bacterial vaccines.
    Corbel MJ
    Dev Biol Stand; 1996; 87():113-24. PubMed ID: 8854008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virus-vectored influenza virus vaccines.
    Tripp RA; Tompkins SM
    Viruses; 2014 Aug; 6(8):3055-79. PubMed ID: 25105278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potency assays for therapeutic live whole cell cancer vaccines.
    Petricciani J; Egan W; Vicari G; Furesz J; Schild G
    Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine.
    Luke TC; Hoffman SL
    J Exp Biol; 2003 Nov; 206(Pt 21):3803-8. PubMed ID: 14506215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New technologies for making vaccines.
    Ellis RW
    Vaccine; 1999 Mar; 17(13-14):1596-604. PubMed ID: 10194811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Live attenuated vaccines for human use.
    Cryz SJ
    Curr Opin Biotechnol; 1992 Jun; 3(3):298-302. PubMed ID: 1368409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
    Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F
    Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory pathways for vaccines for developing countries.
    Milstien J; Belgharbi L
    Bull World Health Organ; 2004 Feb; 82(2):128-33. PubMed ID: 15042235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active and passive immunity, vaccine types, excipients and licensing.
    Baxter D
    Occup Med (Lond); 2007 Dec; 57(8):552-6. PubMed ID: 18045976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conjugate-like immunogens produced as protein capsular matrix vaccines.
    Thanawastien A; Cartee RT; Griffin TJ; Killeen KP; Mekalanos JJ
    Proc Natl Acad Sci U S A; 2015 Mar; 112(10):E1143-51. PubMed ID: 25699685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines.
    Cryz SJ; Fürer E; Germanier R
    Dev Biol Stand; 1983; 53():67-72. PubMed ID: 6873478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. WHO Expert Committee on Biological Standardization. Forty-fifth report.
    World Health Organ Tech Rep Ser; 1995; 858():1-101, back cover. PubMed ID: 8650946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Applications and challenges of multivalent recombinant vaccines.
    Naim HY
    Hum Vaccin Immunother; 2013 Mar; 9(3):457-61. PubMed ID: 23249651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Licensing and control authority batch release of influenza vaccine in Germany in accordance with EEC regulations.
    Weeke-Lüttmann M
    Eur J Epidemiol; 1994 Aug; 10(4):513-4. PubMed ID: 7843372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.
    Viret JF; Dietrich G; Favre D
    Vaccine; 2004 Jun; 22(19):2457-69. PubMed ID: 15193410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.